- IMUNON's innovative treatment, IMNN-001, reaches Phase 3 stage following FDA protocol alignment.
- New survival data from Phase 2 study to be presented at ASCO 2025.
- IMNN-001 offers a novel IL-12 immunotherapy approach for advanced ovarian cancer.
IMUNON Inc. (IMNN, Financial) recently announced that the abstract detailing new survival data from its Phase 2 OVATION 2 Study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study involves the use of IMNN-001, an innovative IL-12 DNA plasmid vector, designed to treat newly diagnosed advanced ovarian cancer. The meeting is scheduled for May 30 to June 3, 2025, in Chicago, Illinois.
The company has also achieved a significant milestone by aligning with the U.S. Food and Drug Administration (FDA) on the protocol for its Phase 3 OVATION 3 clinical trial. Trial site activation for this pivotal study is currently underway.
IMNN-001 utilizes IMUNON's proprietary TheraPlas® technology platform, encasing the IL-12 DNA plasmid vector in nanoparticles. This innovative delivery system ensures persistent and localized production of the IL-12 protein within the tumor microenvironment, stimulating a robust anti-cancer immune response.
IMNN-001 is notable as it is the first and only IL-12 immunotherapy to show clinical effectiveness in frontline treatment for Stage III/IV advanced ovarian cancer, an area that has not seen treatment innovation for over 25 years. Dr. Premal H. Thaker from Washington University School of Medicine will present the promising new data at the ASCO meeting.
The presentation of the OVATION 2 Study results at ASCO signifies the clinical importance and potential breakthrough of IMNN-001 in ovarian cancer treatment. Investors and the medical community keenly await the disclosure of detailed survival metrics during the June 3rd session.
IMUNON's market cap currently stands at approximately $12.4 million, a figure considered low given the promising clinical progress and the commercial potential of IMNN-001 in the treatment of advanced ovarian cancer.
